Physician profile
Tara Monday
NPI 1063740249
$805.40
in general payments reported to CMS, 2019-2025
15 companies · $83.66 in 2025
The $83.66 reported for 2025 was less than what a typical Adolescent Medicine (Pediatrics) provider received nationally (typical 2025 total: $99.31).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $100 · 2021: $43.44 · 2022: $18.83 · 2023: $96.92 · 2024: $314 · 2025: $83.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $494.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $241.90 | 2019-2025 | Dyanavel Xr |
| Pfizer INC. | $122.75 | 2023-2025 | |
| Neos Therapeutics, LP | $78.80 | 2019-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Supernus Pharmaceuticals, INC. | $77.49 | 2024 | Qelbree |
| Seqirus USA INC | $56.80 | 2023-2024 | Flucelvax, Flucelvax Quadrivalent |
| Ironshore Pharmaceuticals INC. | $43.47 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $43.42 | 2019-2024 | Gardasil, Gardasil 9, Vaxelis |
| Cranial Technologies, INC | $30.53 | 2021-2025 | Doc Band |
| Astrazeneca Pharmaceuticals LP | $17.32 | 2024 | Flumist Quadrivalent |
| Alk-Abello, INC | $16.79 | 2023 | Odactra, Ragwitek, Grastek |
| Noven Therapeutics, LLC | $16.18 | 2024 | Xelstrym |
| Rhodes Pharmaceuticals L.P. | $15.65 | 2019 | |
| Shire North American Group INC | $15.50 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.52 | 2019 | |
| Kaleo, INC. | $14.28 | 2023 | Auvi-Q |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Monday listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.